Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 48Lung Neoplasms 24Carcinoma, Hepatocellular 24Small Cell Lung Carcinoma 16Urinary Bladder Neoplasms 12Cholangiocarcinoma 12Breast Neoplasms 10Liver Neoplasms 9Biliary Tract Neoplasms 9Neoplasms 8Neoplasm Metastasis 8Pancreatic Neoplasms 7Carcinoma 6Endometrial Neoplasms 5Colorectal Neoplasms 5Triple Negative Breast Neoplasms 4Non-Muscle Invasive Bladder Neoplasms 4Gallbladder Neoplasms 4Carcinoma, Transitional Cell 4Ovarian Neoplasms 3Neoplasms by Site 3Carcinoma, Renal Cell 3Bile Duct Neoplasms 3Adenocarcinoma 3Thyroid Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Respiratory Tract Neoplasms 2Pathologic Complete Response 2

Interventions

durvalumab 1Gemcitabine 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced or Metastatic Solid Tumours × durvalumab × 90 days × Clear all
NCT04999969 2026-04-30

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

AstraZeneca

Phase 2 Active not recruiting
126 enrolled 30 charts
Other solid neoplasm

Locally Advanced or Metastatic Solid Tumours

Data powered by HemOnc (CC BY 4.0) Colophon âš¡